Download full-text PDF |
Source |
---|
J Cardiovasc Pharmacol
March 1996
Department of Surgery, Erasmus University, Rotterdam, The Netherlands.
The serotonin-2 receptor antagonist ketanserin has been suggested to diminish arteriosclerotic development by its effect on platelet function and on vascular smooth muscle cells. We investigated the ability of ketanserin in reducing immune-mediated arteriosclerosis using the BN-WAG and WAG-BN rat aortic transplantation models. Ketanserin (10 mg/kg/day) administered in drinking water significantly reduced posttransplant arteriosclerotic thickening of the intima in the BN-WAG rat model to 102 +/- 23 mu m as compared with 171 +/- 60 mu m in untreated BN-WAG allografts 8 weeks posttransplantation (p < 0.
View Article and Find Full Text PDFClin Transplant
February 1996
Department of Nephrology, Bialystok Medical School, Poland.
We have recently shown that ketanserin, an antagonist of peripheral serotonin 5-HT2 receptors lowers blood erythropoietin (Epo) levels in some chronic hemodialysis patients. Based on this finding, a preliminary study was undertaken to investigate the effect of a 3-week oral ketanserin administration on serum Epo concentration and relevant hematological parameters in 4 renal allograft recipients with posttransplant erythrocytosis (PTE). We found a marked decrease in Epo concentrations following ketanserin administration, from 48% to 76% of the abnormally elevated pretreatment values with subsequent increases at 3 weeks after discontinuation of the drug in all patients studied.
View Article and Find Full Text PDFTransplant Proc
October 1990
Organ Transplantation Surgical Clinic, Aristotelian University of Thessaloniki, Hippokation Hospital, Greece.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!